SUMICHEM - Fundamental Analysis: Financial Health & Valuation
← Back to ListKey Parameters
⭐ Fundamental Rating: 3.2
✅ Positive
Sumitomo Chemical India has demonstrated strong revenue growth, exceeding analyst estimates by 13% in the most recent quarter and achieving a substantial increase in PAT. The company also offers a solid ROE of 17.6% and ROCE of 23.5%, signaling efficient capital utilization and profitability.
⚠️ Limitation
Despite positive momentum, the stock trades at a premium valuation indicated by a P/E ratio of 44.5 and a PEG ratio of 13.7, reflecting growth expectations that may not be fully priced in. The company's debt-to-equity ratio of 0.02 is low but offers little margin for error during economic downturns.
📉 Company Negative News
Recent news highlights a shift in price momentum and mixed technical signals, indicating potential volatility. Furthermore, the approval of a ₹1.30 dividend coupled with a board reshuffle may not be viewed as particularly exciting investors.
📈 Company Positive News
The company reported revenue beat exceeding analyst estimates by 13%, which is a positive indicator of its operational performance. This robust revenue growth is complemented by dividend announcement of ₹1.30 per share for shareholders.
🏭 Industry
The Indian chemicals industry is experiencing moderate growth driven by rising domestic demand and increasing exports. However, the sector faces challenges including fluctuating raw material prices and intensifying competition from both domestic and international players.
🧾 Conclusion
Given the current valuation metrics and recent positive news, a potential entry zone could be around 460-480 ₹, representing a slight undervaluation relative to its earnings growth. A long-term holding strategy focusing on capital appreciation is recommended, monitoring revenue growth and margin expansion for confirmation of sustained performance. The stock remains a moderate risk investment due to high valuation multiples.